Volume 18, Issue 3, Pages 137 – 204 (2019)

Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung

Case Reports, Volume 18, Issue 3, Pages 137 – 204 (2019)

The advent of immunotherapy in oncology has led to the emergence of a new spectrum of adverse effects. A number of these have the potential to contribute to life-threatening outcomes; and therefore require prompt identification and aggressive treatment to optimise management. In this report, we describe a case of pembrolizumab-induced CTCAE (common toxicity criteria for adverse events) grade 4 myositis in a non-small cell lung cancer patient.

Please subscribe to see more.
Subscribe
Already a member? Log in here

Life threatening pembrolizumabinduced myositis in a patient treated for advanced adenocarcinoma of the lung Read More

Pardon My French

Correspondence, Volume 18, Issue 3, Pages 137 – 204 (2019)

Cama et al’s review of pneumothorax management was excellent, especially their elegant depiction of chest tube diameter in comparison to the intercostal space, as measured in French gauge. The use of gauge is medicine is confusing due to differing systems and seemingly random increments. This diagram neatly shows that French gauge (Fr) is directly proportional to diameter, as the external diameter of the tube in millimetres is the gauge multiplied by three. For example, a 15 Fr chest tube has an external diameter of 5mm.

Pardon My French Read More

Shopping Basket
Scroll to Top

Start typing and press enter to search

Start typing and press enter to search